Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia
Friedrich Stölzel(German Cancer Research Center), James M. Allan(University of York), Heidi Altmann(Technische Universität Dresden), Manja Wobus(Heidelberg University), Lani F. Wu(University of California, San Francisco), Felipe Prósper(Institute of Human Genetics), Abrar Alharbi(Newcastle University), Sara Villar(Hospital de Sant Pau), Catherine Park(Newcastle University), Christoph Röllig(University Hospital Carl Gustav Carus), Martin Bornhäuser(Technische Universität Dresden), Joaquín Martínez‐López(Hospital Universitario 12 De Octubre), Emily Bowes(Newcastle University), Amber Robinson(Newcastle University), Manja Meggendorfer(Université Paris-Sud), Torsten Haferlach(Martin Luther Christian University), Sarah Fordham(Newcastle University), Desireé Kunadt(University Hospital Carl Gustav Carus), Gail Jones(National Health Service), Olaf Heidenreich(Princess Máxima Center), Lisa Wagenführ(University Hospital Carl Gustav Carus), Emmanouela-Niki Soura(Newcastle University), Daniel Allsop(Newcastle University), Hayden L. Bell(Newcastle University), Leo Ruhnke(Krankenhaus Dresden-Friedrichstadt), Claire Elstob(Newcastle University), Steven J. Altschuler(University of California, San Francisco), Kenan Onel(Icahn School of Medicine at Mount Sinai), Tobias Menne(Newcastle upon Tyne Hospitals NHS Foundation Trust), Rachel E. Piddock(University of East Anglia), Zuzanna Bziuk(Newcastle University), Rosa Ayala(Hospital Universitario 12 De Octubre), Graham Jackson(Newcastle College), Claudia Dill(Technische Universität Dresden), Devi Nandana(Newcastle University), Jude Fitzgibbon(Queen Mary University of London), Wei‐Yu Lin(Newcastle University), Beñat Ariceta(Navarre Institute of Health Research), Helen J. Blair(APC Microbiome Institute), Brigitte Mohr(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Mohd Fadly(Newcastle University), Helen Marr(Freeman Hospital), Thahira Rahman(Centre for Life), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 9
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2
|Cell|2020|2.3k
Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits
|Nature Genetics|2018|1.5k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Teclistamab in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2022|1.2k